<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology.
...read full article on Benzinga
